New Nasal Spray Shows Promise in Restoring Lost Sense of Smell

DELRAY BEACH, Fla. – February 17, 2026 – In a significant development for millions suffering from persistent smell loss, Cyrano Therapeutics today announced positive results from a mid-stage clinical trial for its novel intranasal therapy, CYR-064. The company reported that its Phase 2 FLAVOR trial successfully met its primary safety goals and demonstrated notable improvements in patients' ability to smell, paving the way for late-stage development of what could become the first-ever approved drug for post-viral hyposmia.

Hyposmia, a diminished sense of smell, has become an increasingly prevalent condition, particularly in the wake of the COVID-19 pandemic. For many, the loss is temporary, but for a substantial population, it persists for months or years, creating a cascade of related health and quality-of-life issues. The successful trial of CYR-064 represents a beacon of hope for this large and underserved patient community.

The randomized, double-blind, placebo-controlled study involved 151 patients across 14 U.S. sites who had experienced smell loss for at least six months following a viral infection. The positive topline data supports Cyrano's plan to advance the therapy into a larger Phase 3 trial in the second half of 2026.

The Overlooked Crisis of Sensory Loss

The inability to smell is far more than a simple inconvenience. It fundamentally alters one's perception of the world and carries significant risks. An estimated 60 million people in the United States, Europe, and Japan suffer from persistent post-viral hyposmia, a number that swelled dramatically from pre-pandemic figures. This condition is intrinsically linked to a loss of taste, as the perception of flavor is largely dependent on olfactory input.

"Once a person has lost their sense of smell for as long as 6 months, the chances become extremely small that their sense of smell will return," said Rick Geoffrion, President and CEO of Cyrano Therapeutics, in a statement. "When the sense of smell is lost, people also lose up to 80% of their perception of taste. So in general we are talking about the impairment of as many as 2 out of the main 5 human senses."

The consequences are profound. Patients often report nutritional deficits due to a lack of enjoyment in food, leading to unintended weight loss or poor dietary choices. The condition is also strongly associated with an increased risk of depression and social isolation. Furthermore, the inability to detect environmental hazards like gas leaks, smoke from a fire, or spoiled food poses a direct threat to personal safety. For older adults, research has linked persistent smell loss to an increased risk of cognitive decline and mortality.

Until now, the treatment landscape has been barren. Patients are often told to simply wait and see if the sense returns, or they are offered therapies with limited evidence of efficacy, such as olfactory training or off-label use of corticosteroids. CYR-064 aims to fill this critical void.

A Regenerative Approach in a Nasal Spray

At the heart of Cyrano's innovation is a novel formulation and delivery system for a well-established drug. CYR-064 is an intranasal soft-mist spray containing theophylline, a broad-spectrum phosphodiesterase (PDE) inhibitor. The drug works by enhancing the excitability of olfactory neurons, the specialized cells in the nasal cavity responsible for detecting odors. The goal is not just to manage symptoms but to potentially restore function through a regenerative mechanism.

While oral theophylline has been studied for smell disorders in the past, its use has been limited by systemic side effects. Cyrano's patent-protected approach utilizes a targeted delivery system designed to deposit the drug directly onto the olfactory epithelium, maximizing its therapeutic effect while minimizing absorption into the bloodstream. This precision is achieved through a combination of advanced pump and spray technology, a key differentiator from previous attempts to treat the condition.

"We now have the first randomized clinical trial data evaluating a targeted regenerative therapy for post-viral smell loss," noted Dr. Mas Takashima, Chairman of the Department of Otolaryngology at Houston Methodist Hospital and the trial's Primary Investigator. "We currently have no effective options for the tens of millions of patients... The results of this trial show that CYR-064 may one day become the first front-line treatment for this serious condition."

Charting a Course Through Clinical Trials

The success of the Phase 2 FLAVOR trial provides the first robust, placebo-controlled evidence that a pharmaceutical agent can safely improve function in patients with long-term post-viral hyposmia. The trial's primary endpoint was to establish the safety and tolerability of CYR-064, which it achieved with no treatment-related serious adverse events reported.

Crucially, the therapy also met multiple prespecified secondary efficacy endpoints, demonstrating what the company describes as "durable improvements in smell function." While Cyrano plans to release the detailed data at a future medical conference, the topline announcement is a pivotal validation of its scientific approach. The company is now preparing for a much larger Phase 3 study, the final step before seeking regulatory approval.

Cyrano Therapeutics may also have an accelerated path to market. The company has previously indicated it may pursue a 505(b)(2) regulatory pathway with the U.S. Food and Drug Administration (FDA). This pathway allows a drug developer to rely, in part, on the FDA's previous findings of safety and efficacy for an already-approved drug—in this case, theophylline. This could potentially streamline the development and review process, bringing the therapy to patients sooner than a traditional New Drug Application for a completely novel compound.

A First-in-Class Therapy for a Growing Market

Should CYR-064 successfully navigate Phase 3 trials and gain FDA approval, it would enter a market with zero competition and immense unmet need. The market for treating chronic smell and flavor loss is projected to grow substantially, with some analysts estimating its value could exceed $6 billion by the early 2030s. This growth is fueled by the rising prevalence of post-viral syndromes and a greater understanding of the condition's debilitating effects.

Cyrano Therapeutics, a private venture-backed company founded in 2014, appears well-positioned to capitalize on this opportunity. The company has secured nearly $22 million in funding to date, including a recent $9 million Series B round completed in January 2024, to fund its clinical development. It has also demonstrated commercial foresight by granting Kyorin Pharmaceutical an option to license CYR-064 in Japan, securing a potential foothold in a key international market.

The positive Phase 2 results represent more than just a corporate milestone for Cyrano; they signify a potential paradigm shift for a long-neglected patient population. While the path to regulatory approval remains rigorous, this announcement marks the most promising step forward to date in the quest to medically treat the loss of one of our most vital senses.